Details of Disease

General Information of Disease (ID: DISP4D1R)

• Disease Name: Anaplastic large cell lymphoma
• Synonyms: anaplastic large cell lymphoma; CD30 Positive anaplastic large cell lymphoma; Ki-1 lymphoma; Ki-1+ ALCL; primary systemic ALCL; Ki-1 positive anaplastic large cell lymphoma; ALCL; CD30 positive anaplastic large cell lymphoma; sACL; Ki-1+ anaplastic large cell lymphoma
• Disease Class: 2A90: Mature T-cell lymphoma
• Definition: Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell non-Hodgkin lymphoma, belonging to the group of CD30-positive lymphoproliferative disorders, which affects lymph nodes and extranodal sites. It is comprised of two sub-types, based on the expression of a protein called anaplastic lymphoma kinase (ALK): ALK positive and ALK negative ALCL.
• Disease Hierarchy:
  DISCDT4E: Peripheral T-cell lymphoma
  DISP4D1R: Anaplastic large cell lymphoma
• ICD Code:
  ICD-11: ICD-11: 2A90.A
  ICD-10: ICD-10: C84.6
  Expand ICD-11: '2A90.A
  Expand ICD-10: 'C84.6
• Disease Identifiers:
  MONDO ID: MONDO_0020325
  MESH ID: D017728
  UMLS CUI: C0206180
  MedGen ID: 61533
  HPO ID: HP:0012193
  SNOMED CT ID: 53237008

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Brigatinib	DM7W94S	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TRBC1	DM1ZK4W	Phase 1/2	CAR T Cell Therapy	[2]
ICAR30 T cells	DM3YZCV	Phase 1	CAR T Cell Therapy	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 26 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
HSP90AA1	TT78R5H	Limited	Biomarker	[4]
WAS	TTE8T73	Limited	Altered Expression	[5]
JUN	TTS7IR5	moderate	Altered Expression	[6]
STAT3	TTHJT3X	moderate	Altered Expression	[7]
ANPEP	TTPHMWB	Strong	Biomarker	[8]
ATIC	TT9NVXQ	Strong	Genetic Variation	[9]
BACH1	TT2ME4S	Strong	Biomarker	[10]
CCR3	TTD3XFU	Strong	Altered Expression	[11]
CCR8	TTE836A	Strong	Altered Expression	[12]
CD52	TTQT5S9	Strong	Altered Expression	[13]
CEBPB	TTUI35N	Strong	Biomarker	[14]
CYP51A1	TT67TDP	Strong	Biomarker	[15]
DUSP5	TTZN92A	Strong	Genetic Variation	[16]
E2F2	TT5FYX0	Strong	Biomarker	[10]
EML4	TT92GY4	Strong	Biomarker	[17]
GZMB	TTKEPHX	Strong	Altered Expression	[18]
JAK3	TTT7PJU	Strong	Altered Expression	[19]
NCAM1	TTVXPHT	Strong	Biomarker	[20]
PNLIP	TTXMY0J	Strong	Biomarker	[21]
PRSS1	TT2WR1T	Strong	Biomarker	[22]
PTPN6	TT369M5	Strong	Altered Expression	[23]
RORC	TTGV6LY	Strong	Biomarker	[24]
RPE65	TTBOH16	Strong	Genetic Variation	[25]
SQLE	TTE14XG	Strong	Altered Expression	[26]
TWIST1	TTX1MY7	Strong	Biomarker	[27]
ID2	TTW8A5N	Definitive	Altered Expression	[28]

This Disease Is Related to 60 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
BATF3	OTI61WXQ	Limited	Biomarker	[29]
CCNT1	OTDYVGCP	Limited	Altered Expression	[30]
GTF2H4	OTPD1DIU	Limited	Biomarker	[31]
HOXC5	OTPQTLKZ	Limited	Altered Expression	[32]
HOXC6	OTBCRAZV	Limited	Altered Expression	[32]
TNFSF8	OTDYGDJ3	Limited	Altered Expression	[33]
BCL10	OT47MCLI	Disputed	Altered Expression	[34]
FOSB	OTW6C05J	moderate	Altered Expression	[6]
JUNB	OTG2JXV5	moderate	Altered Expression	[6]
JUND	OTNKACJD	moderate	Altered Expression	[6]
ADARB1	OTGKSZEV	Strong	Altered Expression	[35]
ARNT	OTMSIEZY	Strong	Biomarker	[36]
BATF	OT9VSD2D	Strong	Altered Expression	[24]
BCL3	OT1M5B95	Strong	Altered Expression	[37]
BLNK	OTSSPF6F	Strong	Altered Expression	[38]
CARS1	OTOUZF6O	Strong	Altered Expression	[9]
CARS2	OTGLZOFP	Strong	Genetic Variation	[9]
CHP1	OTHTXN1A	Strong	Genetic Variation	[39]
CIB1	OT4BVCRU	Strong	Altered Expression	[40]
CKAP4	OTDUC9ME	Strong	Genetic Variation	[25]
CLIP1	OTTGAEJE	Strong	Altered Expression	[41]
CLTC	OTBFASMA	Strong	Genetic Variation	[42]
CLTCL1	OT6W5BNR	Strong	Genetic Variation	[9]
COL15A1	OTTFKK18	Strong	Altered Expression	[41]
CROT	OTWK68MM	Strong	Biomarker	[43]
DOK2	OTIJ38UF	Strong	Biomarker	[44]
DUSP22	OTEZ3U85	Strong	Genetic Variation	[25]
HERPUD1	OT9EROL6	Strong	Genetic Variation	[45]
HRNR	OT560QR5	Strong	Altered Expression	[46]
IRF4	OT1DHQ1P	Strong	Biomarker	[16]
MAGEH1	OTVE05K7	Strong	Altered Expression	[41]
MCC	OTQVI1EM	Strong	Biomarker	[47]
MSN	OTZJ4J6G	Strong	Biomarker	[48]
NAPSA	OT6F8IAL	Strong	Biomarker	[49]
PDLIM2	OTEURRPD	Strong	Altered Expression	[50]
PDLIM7	OTAZVODU	Strong	Biomarker	[51]
PRDM8	OTRA3265	Strong	Genetic Variation	[52]
PRF1	OTFVXD7H	Strong	Genetic Variation	[53]
PRSS2	OTOMVUWL	Strong	Biomarker	[22]
PRSS3	OTN3S5YB	Strong	Biomarker	[22]
PWWP3A	OTXQVL4U	Strong	Biomarker	[13]
RBAK	OTYJ6EAU	Strong	Biomarker	[10]
RGL4	OTTAEWCF	Strong	Genetic Variation	[54]
RHOV	OTW4N3QN	Strong	Genetic Variation	[39]
RNF213	OT4OVE9O	Strong	Genetic Variation	[9]
RPL18A	OTKBMVCX	Strong	Altered Expression	[55]
RPTN	OTOAA25U	Strong	Altered Expression	[46]
SERPINB9	OTJ811IF	Strong	Altered Expression	[56]
SKAP1	OTD4ZKAL	Strong	Biomarker	[44]
SMG1	OTTS3SXE	Strong	Altered Expression	[57]
TCHHL1	OTAMOJGN	Strong	Altered Expression	[46]
TFG	OT2KJENI	Strong	Genetic Variation	[58]
TIA1	OTGPN3P8	Strong	Altered Expression	[59]
TMOD1	OTTRYF9Y	Strong	Biomarker	[60]
TP53INP1	OT2363Z9	Strong	Altered Expression	[10]
TPM3	OT5RU5G6	Strong	Altered Expression	[61]
TRAP1	OTNG0L8J	Strong	Biomarker	[62]
TRIM32	OTJOV0PG	Strong	Biomarker	[10]
TSPYL2	OTGGW2EF	Strong	Biomarker	[63]
GNLY	OTZJKA8C	Definitive	Biomarker	[64]

References

• [1] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [2] ClinicalTrials.gov (NCT03590574) Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma
• [3] ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas
• [4] CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells.Am J Pathol. 2017 Jan;187(1):163-175. doi: 10.1016/j.ajpath.2016.09.007. Epub 2016 Nov 19.
• [5] Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma.Nat Med. 2019 Jan;25(1):130-140. doi: 10.1038/s41591-018-0262-9. Epub 2018 Dec 3.
• [6] The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.Cancers (Basel). 2018 Mar 28;10(4):93. doi: 10.3390/cancers10040093.
• [7] PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.Mod Pathol. 2020 Mar;33(3):324-333. doi: 10.1038/s41379-019-0336-3. Epub 2019 Aug 5.
• [8] CD13+ anaplastic large cell lymphoma with leukemic presentation and additional chromosomal abnormality.Diagn Cytopathol. 2010 Feb;38(2):141-6. doi: 10.1002/dc.21170.
• [9] Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.Genes Chromosomes Cancer. 2002 Aug;34(4):354-62. doi: 10.1002/gcc.10033.
• [10] Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.Hum Pathol. 2014 Oct;45(10):1995-2005. doi: 10.1016/j.humpath.2014.06.012. Epub 2014 Jun 30.
• [11] Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Szary Syndrome.Acta Derm Venereol. 2019 Jul 1;99(9):809-812. doi: 10.2340/00015555-3207.
• [12] Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):580-9. doi: 10.1097/PAI.0000000000000118.
• [13] CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.Haematologica. 2013 Aug;98(8):1250-8. doi: 10.3324/haematol.2012.081935. Epub 2013 May 28.
• [14] Identification of C/EBP target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.PLoS One. 2013 May 31;8(5):e64544. doi: 10.1371/journal.pone.0064544. Print 2013.
• [15] Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.Cancer Lett. 2019 Apr 28;448:84-93. doi: 10.1016/j.canlet.2019.02.002. Epub 2019 Feb 8.
• [16] DUSP22-IRF4 rearrangement in AIDS-associated ALK-negative anaplastic large cell lymphoma.BMJ Case Rep. 2019 Sep 30;12(9):e230641. doi: 10.1136/bcr-2019-230641.
• [17] Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.Cancers (Basel). 2018 Mar 30;10(4):99. doi: 10.3390/cancers10040099.
• [18] Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.Mol Cancer. 2014 Aug 29;13:199. doi: 10.1186/1476-4598-13-199.
• [19] IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.Am J Pathol. 2009 Aug;175(2):825-34. doi: 10.2353/ajpath.2009.080982. Epub 2009 Jul 16.
• [20] CD56-positive adult T-cell leukemia/lymphoma: a case report and a review of the literature.Med Mol Morphol. 2015 Mar;48(1):54-9. doi: 10.1007/s00795-014-0072-1. Epub 2014 Mar 28.
• [21] Subcutaneous panniculitic T-cell lymphoma is a tumor of cytotoxic T lymphocytes.Hum Pathol. 1998 Apr;29(4):397-403. doi: 10.1016/s0046-8177(98)90122-8.
• [22] Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines.Mol Cancer. 2008 Jan 7;7:2. doi: 10.1186/1476-4598-7-2.
• [23] SHP1 tyrosine phosphatase negatively regulates NPM-ALK tyrosine kinase signaling.Blood. 2006 May 15;107(10):4130-8. doi: 10.1182/blood-2005-06-2421. Epub 2006 Feb 9.
• [24] The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9. Epub 2018 Mar 28.
• [25] ALCL by any other name: the many facets of anaplastic large cell lymphoma.Pathology. 2020 Jan;52(1):100-110. doi: 10.1016/j.pathol.2019.09.007. Epub 2019 Nov 6.
• [26] Squalene accumulation in cholesterol auxotrophic lymphomas prevents oxidative cell death.Nature. 2019 Mar;567(7746):118-122. doi: 10.1038/s41586-019-0945-5. Epub 2019 Feb 13.
• [27] Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012 Apr;24(4):852-8. doi: 10.1016/j.cellsig.2011.11.020. Epub 2011 Dec 8.
• [28] The helix-loop-helix protein Id2 is expressed differentially and induced by myc in T-cell lymphomas.Cancer. 2008 Feb 1;112(3):552-61. doi: 10.1002/cncr.23196.
• [29] Ectopic expression of transcription factor BATF3 induces B-cell lymphomas in a murine B-cell transplantation model.Oncotarget. 2018 Mar 23;9(22):15942-15951. doi: 10.18632/oncotarget.24639. eCollection 2018 Mar 23.
• [30] CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.J Pathol. 2004 Aug;203(4):946-52. doi: 10.1002/path.1588.
• [31] Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-kappaB p52, which is associated with hyperphosphorylated Bcl-3.Cancer Sci. 2005 Aug;96(8):487-97. doi: 10.1111/j.1349-7006.2005.00078.x.
• [32] HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas.Am J Pathol. 1997 Oct;151(4):1067-74.
• [33] The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.Cancer Res. 2006 Sep 15;66(18):9002-8. doi: 10.1158/0008-5472.CAN-05-4101.
• [34] BCL10 down-regulation in peripheral T-cell lymphomas.Hum Pathol. 2012 Dec;43(12):2266-73. doi: 10.1016/j.humpath.2012.03.024. Epub 2012 Jul 19.
• [35] CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma.Leuk Lymphoma. 2006 Oct;47(10):2181-8. doi: 10.1080/10428190600773396.
• [36] The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappaB-dependent transcription.Science. 2009 Jan 9;323(5911):251-5. doi: 10.1126/science.1162818.
• [37] Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.Int J Hematol. 2005 Dec;82(5):397-405. doi: 10.1532/IJH97.05045.
• [38] The histologic, immunohistochemical, and genetic features of classical Hodgkin lymphoma and anaplastic large cell lymphoma with aberrant T-cell/B-cell antigen expression.Hum Pathol. 2019 Feb;84:309-320. doi: 10.1016/j.humpath.2018.10.003. Epub 2018 Oct 17.
• [39] Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.Blood. 2018 May 10;131(19):2120-2124. doi: 10.1182/blood-2017-12-821009. Epub 2018 Mar 5.
• [40] Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma.Clin Cancer Res. 2003 Mar;9(3):1121-8.
• [41] Restin in Hodgkin's disease and anaplastic large cell lymphoma.Leuk Lymphoma. 1993 Dec;12(1-2):21-6. doi: 10.3109/10428199309059567.
• [42] ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma.Blood. 2003 Oct 1;102(7):2638-41. doi: 10.1182/blood-2003-04-1050. Epub 2003 May 15.
• [43] Involvement of Cot activity in the proliferation of ALCL lymphoma cells.Biochem Biophys Res Commun. 2011 Aug 12;411(4):655-60. doi: 10.1016/j.bbrc.2011.06.157. Epub 2011 Jun 29.
• [44] Intracellular TCR-signaling pathway: novel markers for lymphoma diagnosis and potential therapeutic targets.Am J Surg Pathol. 2014 Oct;38(10):1349-59. doi: 10.1097/PAS.0000000000000309.
• [45] Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling.Cancers (Basel). 2018 Dec 12;10(12):509. doi: 10.3390/cancers10120509.
• [46] Expression of the novel intermediate filament-associated protein restin in Hodgkin's disease and anaplastic large-cell lymphoma.Blood. 1992 Dec 1;80(11):2891-6.
• [47] Conjugation of DM1 to anti-CD30 antibody has potential antitumor activity in CD30-positive hematological malignancies with lower systemic toxicity.MAbs. 2019 Aug/Sep;11(6):1149-1161. doi: 10.1080/19420862.2019.1618674. Epub 2019 Jun 4.
• [48] Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma.Hum Pathol. 2004 Aug;35(8):1038-41. doi: 10.1016/j.humpath.2004.05.006.
• [49] Aberrant expression of napsin A in a subset of malignant lymphomas.Histol Histopathol. 2016 Feb;31(2):213-21. doi: 10.14670/HH-11-669. Epub 2015 Sep 24.
• [50] Inactivation of the putative ubiquitin-E3 ligase PDLIM2 in classical Hodgkin and anaplastic large cell lymphoma.Leukemia. 2017 Mar;31(3):602-613. doi: 10.1038/leu.2016.238. Epub 2016 Aug 19.
• [51] Epstein-Barr virus in CD30 anaplastic large cell lymphoma involving the skin and lymphomatoid papulosis in South Korea.Int J Dermatol. 2006 Nov;45(11):1312-6. doi: 10.1111/j.1365-4632.2006.02951.x.
• [52] Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.Histopathology. 2019 Mar;74(4):654-662. doi: 10.1111/his.13783. Epub 2019 Jan 31.
• [53] Monoallelic mutations of the perforin gene may represent a predisposing factor to childhood anaplastic large cell lymphoma.J Pediatr Hematol Oncol. 2014 Aug;36(6):e359-65. doi: 10.1097/MPH.0000000000000073.
• [54] Human rgr: transforming activity and alteration in T-cell malignancies.Oncogene. 2002 Aug 1;21(33):5108-16. doi: 10.1038/sj.onc.1205694.
• [55] Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas.Mod Pathol. 2019 Feb;32(2):216-230. doi: 10.1038/s41379-018-0130-7. Epub 2018 Sep 11.
• [56] Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma.Blood. 2002 Jun 15;99(12):4540-6. doi: 10.1182/blood.v99.12.4540.
• [57] NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.Blood. 2006 Sep 15;108(6):2029-36. doi: 10.1182/blood-2005-10-014258. Epub 2006 May 18.
• [58] Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity.Am J Pathol. 2002 Apr;160(4):1487-94. doi: 10.1016/S0002-9440(10)62574-6.
• [59] Cytotoxic molecule expression is predictive of prognosis in Hodgkin's-like anaplastic large cell lymphoma.Histopathology. 2007 May;50(6):705-15. doi: 10.1111/j.1365-2559.2007.02674.x.
• [60] Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma.Blood. 2012 Aug 9;120(6):1274-81. doi: 10.1182/blood-2012-01-405555. Epub 2012 Jun 27.
• [61] Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.Leuk Res. 2008 Mar;32(3):383-93. doi: 10.1016/j.leukres.2007.07.012. Epub 2007 Aug 27.
• [62] Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.Mol Cell Proteomics. 2010 Jul;9(7):1616-32. doi: 10.1074/mcp.M000153-MCP201. Epub 2010 Apr 14.
• [63] Interleukin-2 receptor-directed therapies for cutaneous lymphomas.Hematol Oncol Clin North Am. 2003 Dec;17(6):1449-58. doi: 10.1016/s0889-8588(03)00110-2.
• [64] The expression of granulysin in systemic anaplastic large cell lymphoma in childhood.Leuk Res. 2009 Jul;33(7):908-12. doi: 10.1016/j.leukres.2009.01.032. Epub 2009 Feb 24.